XFOR News and Press, X4 Pharmaceuticals Inc. From 05/07/24

U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood , the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 ...

BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing...

2024-04-29 17:02:33 ET Summary X4 Pharmaceuticals, Inc. received FDA approval for mavorixafor in WHIM syndrome, along with a priority review voucher (typically worth $100M). X4 Pharmaceuticals has announced very premium pricing considering the benefits of mavorixafor and ultra-orp...

2024-04-29 10:24:20 ET More on X4 Pharmaceuticals X4 Pharmaceuticals: PDUFA Excitement Ahead X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05 Seeking Alpha’s Quant Rating on X4 Pharma...

XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with approval Conferenc...

2024-04-26 15:00:06 ET More on the markets SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish Be Greedy When Others Are Fearful, Even If They Are Fearful For A Good Reason BofA watched clients retract $2B last week as th...

2024-04-15 18:21:52 ET Summary X4 Pharmaceuticals, Inc. is awaiting an FDA decision on its lead molecule mavorixafor for the treatment of WHIM syndrome. Mavorixafor is a powerful immune system booster with potential in treating rare immunodeficiency. X4's financial position is...

2024-04-08 10:20:00 ET April 8, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sectors. The newest biotech companies are involved in preventative care...

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23 rd Annual Healthcare Conference b...

2024-03-21 11:35:28 ET X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Conference Call March 21, 2024, 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dr. Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Mark Bald...